Product image of Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) supplied by GNH India

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord

Active Ingredient:
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide
Origin:
EU

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑drug therapy does not provide adequate control.

GNH India supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Accord Healthcare Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord is used in the management of hypertension, acting on the renin‑angiotensin system and vascular smooth‑muscle tone.

  • Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
  • Hypertensive urgency: provides gradual blood‑pressure reduction as part of a stepped‑care approach.
  • Cardiovascular risk reduction: contributes to decreased risk of stroke and myocardial infarction in patients with elevated blood pressure.

How It Works

  • The combination product works through three complementary mechanisms: olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide increases renal excretion of sodium and water, reducing plasma volume. Together these actions produce additive blood‑pressure lowering effects.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness or light‑headedness, especially after standing.
  • Fatigue: general feeling of tiredness.
  • Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure causing fainting.
  • Electrolyte imbalance: significant changes in potassium or sodium levels.
  • Acute kidney injury: sudden decline in renal function.
  • Angio‑edema: rapid swelling of lips, tongue, or airway.
  • Liver enzyme elevation: abnormal liver function tests.

Precautions & Warnings

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

  • Renal function: assess creatinine clearance and adjust if necessary.
  • Electrolytes: monitor potassium and sodium levels regularly.
  • Pregnancy: avoid use; drug is contraindicated in the third trimester.
  • Concomitant antihypertensives: watch for additive blood‑pressure lowering effects.
  • Elderly patients: start at lower dose and titrate cautiously.
  • Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Avoid Interactions

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Accord can interact with several medicines; clinical judgment is required.

Major Interactions (Avoid)

  • Aliskiren: combined use with ACE inhibitors or ARBs in diabetes or renal impairment increases risk of renal dysfunction.
  • Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalaemia.
  • NSAIDs (high dose): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

  • Lithium: may increase serum lithium levels, requiring concentration monitoring.
  • CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine concentrations.
  • Antidiabetic agents: enhanced glucose‑lowering effect may necessitate dose adjustment.

Frequently Asked Questions

Olmesartan Medoxil/Amlodipine/HCTZ Accord is a fixed‑dose combination indicated for the treatment of primary hypertension, especially when blood‑pressure control is not achieved with a single agent. It helps lower both systolic and diastolic pressures and contributes to overall cardiovascular risk management.

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB). It selectively blocks the AT‑1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, which leads to relaxation of blood vessels and reduced fluid retention, supporting the blood‑pressure‑lowering actions of amlodipine and hydrochlorothiazide.

The prescribed dose of Olmesartan Medoxomil/Amlodipine/HCTZ Accord is determined by the treating clinician based on the patient’s blood‑pressure level, response to therapy, and renal function. Dosage adjustments are made according to clinical guidelines and individual tolerability.

The combination is contraindicated in pregnancy, particularly in the second and third trimesters, because ARBs can cause fetal toxicity. Breastfeeding is not recommended unless the benefits outweigh potential risks, and a healthcare professional should evaluate each case.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

A fixed‑dose combination offers the convenience of a single tablet, improving adherence and providing synergistic blood‑pressure reduction. Compared with separate tablets, it reduces pill burden and may lower the risk of missed doses, while delivering comparable efficacy when doses are appropriately matched.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the prescribing clinician’s instructions regarding timing and any dose adjustments.

Serious adverse events can include severe hypotension, acute kidney injury, hyper‑kalaemia, angio‑edema and significant electrolyte disturbances. Prompt medical attention is required if symptoms such as fainting, swelling of the face or throat, or sudden loss of kidney function occur.

Patients with known hypersensitivity to any component, severe renal impairment, hyper‑kalaemia, or those in the second or third trimester of pregnancy should avoid this medication. Clinicians should also exercise caution in elderly patients and those taking interacting drugs.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT